Analyst Naz Rahman of Maxim Group reiterated a Buy rating on Clene, with a price target of $20.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Naz Rahman has given his Buy rating due to a combination of factors that highlight Clene’s promising future. The company is advancing its lead asset, CNM-Au8, a gold-based nanocrystal suspension, in treating neurological disorders such as ALS. The anticipation of near-term data readouts and a subsequent NDA filing in the first quarter of 2026 positions Clene for potential regulatory milestones, which could significantly enhance its market value.
Clene’s strategic financial management, including recent fundraising efforts, ensures sufficient capital to support operations through these critical phases. The Orphan Drug Designation for CNM-Au8 could expedite its review process, potentially leading to an FDA Advisory Committee meeting and approval by the latter half of 2026. Given the limited treatment options for ALS and the promising data from Clene’s clinical trials, Rahman believes CNM-Au8 has a high probability of approval, making Clene’s stock a compelling buy opportunity.
In another report released yesterday, Roth MKM also maintained a Buy rating on the stock with a $30.00 price target.
CLNN’s price has also changed dramatically for the past six months – from $2.660 to $8.520, which is a 220.30% increase.